DSFIR KONINKLIJKE DSM N.V.

dsm-firmenich completes shareholding increase in Andre Pectin to 90.5%

dsm-firmenich completes shareholding increase in Andre Pectin to 90.5%

Press Release

dsm-firmenich completes shareholding increase in

Andre Pectin to 90.5%

Kaiseraugst (Switzerland), Maastricht (Netherlands), April 3, 2025

dsm-firmenich, innovators in nutrition, health, and beauty, today expanded its investment in Yantai DSM Andre Pectin Company Limited (‘Andre Pectin’), increasing its shareholding to 90.5%. Andre Pectin is a leading specialty food ingredient producer.

dsm-firmenich already held 75% of shares in Andre Pectin. Following the latest acquisition of another 15.5% of shares, dsm-firmenich increased its shareholding to 90.5%. The remaining 9.5% of the shares in Andre Pectin continue to be held by Rich Spring Holdings Limited.

Announcements to previous related transactions were made on and .

Financial details of the transaction will not be disclosed. 

About dsm-firmenich

As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people.     

For more information

Media relations

Robin Roothans

tel. +41 (0)79 280 03 96

e-mail

 

Investor relations

Dave Huizing

tel. +31 (0)88 425 7306

e-mail

Forward-looking statements

This press release may contain forward-looking statements with respect to dsm-firmenich’s future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment



EN
03/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KONINKLIJKE DSM N.V.

 PRESS RELEASE

dsm-firmenich cancels its shares following completion of its €1.08 bil...

dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program Press Release dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program Kaiseraugst (Switzerland), Maastricht (Netherlands), February 26 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announces that following the completion of its €1.08 billion share buyback program in 2025, the company has cancelled 12,049,441 shares. As a result, the total number of issued shares has been reduced by approximately 4.5%, from 265,676,388 to 253,62...

 PRESS RELEASE

dsm-firmenich publishes 2025 Integrated Annual Report

dsm-firmenich publishes 2025 Integrated Annual Report Press Release dsm-firmenich publishes 2025 Integrated Annual Report Kaiseraugst (Switzerland), Maastricht (Netherlands), February 20, 2026 dsm-firmenich today announces the publication of its Integrated Annual Report (IAR) for 2025, a year during which the company advanced its innovation-led growth agenda, sharpened its strategic profile, and delivered a good performance. The 2025 IAR offers a comprehensive overview of dsm-firmenich’s financial and non-financial progress during the past year. It details the Group’s performance, inclu...

Guy Sips ... (+3)
  • Guy Sips
  • Mathijs Geerts Danau
  • Wim Hoste
 PRESS RELEASE

dsm-firmenich issues €1.5 billion long-term bonds

dsm-firmenich issues €1.5 billion long-term bonds Press Release dsm-firmenich issues €1.5 billion long-term bonds Kaiseraugst (Switzerland), Maastricht (Netherlands), February 17 2026 dsm-firmenich today announces the successful launch of a €1.5 billion dual-tranche bond issuance, consisting of: €750 million 3.00% fixed-rate notes due 2031€750 million 3.75% fixed-rate notes due 2038   The bonds will be issued by DSM B.V. and guaranteed by DSM-Firmenich AG pursuant to the previously established . The proceeds of the new bonds will be used for refinancing of existing bond maturities. ...

Wim Hoste
  • Wim Hoste

DSM-Firmenich Biting the ANH bullet

The long awaited divestment of ANH disappointed on deal value (EV € 2.2bn, including a potential earn-out of up to € 0.5bn), but creates a group with a much more comprehensive activity and earnings profile. We still appreciate dsm-firmenich for its broad portfolio and market leading positions in consumer-oriented businesses in Nutrition, Health and Beauty. We remind that we have already lowered our target price upon the ANH divestment announcement last week so we maintain our current € 82 target...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch